Table 1.

Patient Characteristics

Patient Factors	PCT (n=14)	No PCT (n=309)	p value
Time to Development of PCT (months) Median (range)	2.98 (1.25–11.25)	na	na
Age at Transplant (years) Median (range)	12 (4–17)	9 (0–18)	.43
Gender Male Female	10 (71%) 4 (29%)	198 (64%) 111 (36%)	.57
Diagnosis ALL AML CML	9 (64%) 3 (21%) 2 (14%)	168 (54%) 125 (40%) 16 (5%)	.18
Disease Risk Group High Intermediate	10 (71%) 4 (29%)	211 (68%) 99 (32%)	.79
Graft Source BM UCB	10 (71%) 4 (29%)	195 (63%) 114 (37%)	.61
Donor Unrelated Sibling Identical Twin Parent/Grandparent	9 (64%) 4 (29%) 0 1 (7%)	197 (64%) 96 (31%) 2 (1%) 14 (5%)	0.97
HLA Match 6/6 5/6 4/6 Missing	8 (57%) 6 (43%) 0 0	163 (53%) 98 (32%) 45 (15%) 3 (1%)	.44
Recipient CMV Serostatus Negative Positive Missing	9 (64%) 5 (36%) 0	153 (49%) 150 (50%) 6 (2%)	.52
Conditioning Intensity MA NMA	14 (100%) 0	310 (99%) 1 (<1%)	1.00
GVHD prophylaxis CSA based Elutriation MTX based Other	11 (79%) 2 (14%) 1 (7%) 0	250 (81%) 34 (11%) 18 (6%) 8 (2%)	.99

na = not applicable, ALL = acute lymphocytic leukemia, AML = acute myelocytic leukemia, CML = chronic myelocytic leukemia, BM = bone marrow, UCB = umbilical cord blood, HLA = human leukeocyte antigen, CMV = cytomegalovirus, MA = myeloablative, NMA = nonmyeloablative, GVHD = graft-versus-host disease, CSA = cyclosporine, MTX = methotrexate, aGVHD = acute graft-versus-host disease, cGVHD = chronic graft-versus-host disease.